Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus

PLoS ONE

Volumn 12, Issue 10, 2017, Pages

  Sastry, Mallika ^a   Zhang, Baoshan ^a   Chen, Man ^a   Joyce, M Gordon ^a   Kong, Wing Pui ^a   Chuang, Gwo Yu ^a   Ko, Kiyoon ^a   Kumar, Azad ^a   Silacci, Chiara ^b   Thom, Michelle ^c   Salazar, Andres M ^d   Corti, Davide ^b,e   Lanzavecchia, Antonio ^b   Taylor, Geraldine ^c   Mascola, John R ^a   Graham, Barney S ^a   Kwong, Peter D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^d Oncovir Inc   (United States)

^e Humabs BioMed SA ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADDAVAX; ADJUPLEX; ALUMINUM HYDROXIDE; CARBOMER; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 71 VG; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SIGMA ADJUVANT SYSTEM; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MOUSE; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH1 CELL; TH2 CELL; VACCINATION; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; PNEUMOVIRUS;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; MICE; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 85032510890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0186854     Document Type: Article

References (52)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013; 380(9859):2095–128. Epub 2012/12/19. https://doi.org/10.1016/s0140-6736(12)61728-0 PMID: 23245604.
2. Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert review of vaccines. 2008; 7(2):249–58. https://doi.org/10.1586/14760584.7.2.249 PMID: 18324893
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. New Engl J Med. 2005; 352(17):1749–59. doi: 10.1056/NEJMoa043951. WOS:000228689000005. PMID: 15858184
4. Graham BS. Biological Challenges and Technological Opportunities for Respiratory Syncytial Virus Vaccine Development. Immunological reviews. 2011; 239(1):149–66. doi: 10.1111/j.1600-065X.2010.00972.x. PMC3023887. PMID: 21198670
5. Jeener E. The three original publications on vaccination against smallpox. Eliot C, editor. New York: P. F. Collier & Son; 1798.
6. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. American journal of epidemiology. 1969; 89(4):435–48. PMID: 4305199
7. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field Evaluation Of a Respiratory Syncytial Virus Vaccine and a Trivalent Parainfluenza Virus Vaccine in a Pediatric Population1. American journal of epidemiology. 1969; 89(4):449–63. https://doi.org/10.1093/oxfordjournals.aje.a120957 PMID: 4305200
8. Murphy BR, Sotnikov A, Paradiso PR, Hildreth SW, Jenson AB, Baggs RB, et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine. 1989; 7(6):533–40. https://doi.org/10.1016/0264-410X(89)90278-8. PMID: 2692334
9. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine. 1990; 8(5):497–502. https://doi.org/10.1016/0264-410X(90)90253-I. PMID: 2251875
10. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013; 342(6158):592–8. Epub 2013/11/02. https://doi.org/10.1126/science.1243283 PMID: 24179220.
11. Stewart-Jones GBE, Thomas PV, Chen M, Druz A, Joyce MG, Kong WP, et al. A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PloS one. 2015; 10(6). WOS:000356835800019.
12. Boyington JC, Joyce MG, Sastry M, Stewart-Jones GB, Chen M, Kong WP, et al. Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. PloS one. 2016; 11(7):e0159709. https://doi.org/10.1371/journal.pone.0159709 PMID: 27463224; PubMed Central PMCID: PMC4963090.
13. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nature communications. 2015; 6:8143. https://doi.org/10.1038/ncomms9143 PMID: 26333350; PubMed Central PMCID: PMC4569726.
14. Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med. 2015; 7(300):300ra126. https://doi.org/10.1126/scitranslmed.aac5745 PMID: 26268313; PubMed Central PMCID: PMCPMC4669850.
15. Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, et al. Improved prefusion stability, optimized codon-usage, and augmented virion packaging enhance the immunogenicity of respiratory syncytial virus (RSV) fusion protein in a vectored vaccine candidate. Journal of virology. 2017. https://doi.org/10.1128/JVI.00189-17 PMID: 28539444.
16. Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly DJ, Frost SD, et al. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund’s adjuvants. PloS one. 2012; 7(4):e35083. https://doi.org/10.1371/journal.pone.0035083 PMID: 22509385; PubMed Central PMCID: PMC3324409.
17. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001; 56(6):498–505. https://doi.org/10.1034/j.1398-9995.2001.056006498.x PMID: 11421893
18. Liang F, Lindgren G, Sandgren KJ, Thompson EA, Francica JR, Seubert A, et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci Transl Med. 2017; 9(393).
19. Wegmann F, Moghaddam AE, Schiffner T, Gartlan KH, Powell TJ, Russell RA, et al. The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice. Clinical and vaccine immunology: CVI. 2015; 22 (9):1004–12. https://doi.org/10.1128/CVI.00736-14 PMID: 26135973; PubMed Central PMCID: PMC4550664.
20. Gualandi GL, Losio NM, Muratori G, E. F. The ability by different preparations of porcine parvovirus to enhance humoral immunity in swine and guinea pigs. Microbiologica. 1988; 11(4):363–9. PMID: 3216795
21. Hoogland MJ, Opriessnig T, Halbur PG. Effects of adjuvants on porcine circovirus type 2-associated lesions. JSHAP. 2006; 14(3):133–9.
22. Tollersrud T, Nørstebø PE, Engvik JP, Andersen SR, Reitan LJ, Lund A. Antibody Responses in Sheep Vaccinated against Staphylococcus aureus Mastitis: A Comparison of Two Experimental Vaccines Containing Different Adjuvants. Veterinary Research Communications. 2002; 26(8):587–600. https://doi.org/10.1023/a:1020960402112 PMID: 12507034
23. Mumford JA, Wilson H, Hannant D, Jessett DM. Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant. Epidemiology and infection. 2009; 112(2):421–37. Epub 05/ 01. https://doi.org/10.1017/S0950268800057848
24. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS pathogens. 2009; 5(4):e1000373. https://doi.org/10.1371/journal.ppat.1000373 PMID: 19360120; PubMed Central PMCID: PMCPMC2660151.
25. Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, Li M, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Journal of Hematology & Oncology. 2017; 10:82. doi: 10.1186/s13045-017-0459-2. PMC5384142. PMID: 28388966
26. Dowling JK, Mansell A. Toll-like receptors: the swiss army knife of immunity and vaccine development. Clin Trans Immunol. 2016; 5:e85. https://doi.org/10.1038/cti.2016.22 PMID: 27350884
27. Nicholls EF, Madera L, Hancock REW. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Annals of the New York Academy of Sciences. 2010; 1213(1):46–61. https://doi.org/10.1111/j.1749-6632.2010.05787.x PMID: 20946578
28. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends in immunology. 2009; 30(1):23–32. https://doi.org/10.1016/j.it.2008.09.006 PMID: 19059004
29. De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: Unraveling a century old mystery. European Journal of Immunology. 2008; 38(8):2068–71. https://doi.org/10.1002/eji.200838648 PMID: 18651701
30. Wang Y, Rahman D, Lehner T. A Comparative Study of Stress-mediated Immunological Functions with the Adjuvanticity of Alum. The Journal of biological chemistry. 2012; 287(21):17152–60. doi: 10.1074/jbc.M112.347179. PMC3366808. PMID: 22474329
31. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-[kappa]B by Toll-like receptor 3. Nature. 2001; 413(6857):732–8. https://doi.org/10.1038/ 35099560 PMID: 11607032
32. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. The Lancet. 2004; 364(9447):1757–65. http://dx.doi.org/10.1016/S0140-6736(04)17398-4.
33. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet. 2007; 369(9580):2161–70. https://doi.org/10.1016/S0140-6736(07)60946-5.
34. Thoelen S, De Clercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine. 2001; 19(17):2400–3. http://dx.doi.org/10.1016/S0264-410X(00)00462-X.
35. Hertz T, Beatty PR, MacMillen Z, Killingbeck SS, Wang C, Harris E. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections. The Journal of Immunology. 2017; 198(10):4025. https://doi.org/10.4049/jimmunol.1700029PMID: 28381638
36. Zhang B, Chen L, Silacci C, Thom M, Boyington JC, Druz A, et al. Protection of calves by a prefusion-stabilized bovine RSV F vaccine. npj Vaccines. 2017; 2(1):7. https://doi.org/10.1038/s41541-017-0005-9 PMID: 29021918
37. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol. 1988; 26(2):153–62. Epub 1988/10/01. PMID: 3183639.
38. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology. 2012; 434 (1):129–36. Epub 2012/10/16. https://doi.org/10.1016/j.virol.2012.09.022 PMID: 23062737; PubMed Central PMCID: PMC3492879.
39. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. American journal of epidemiology. 1938; 27(3):493–7. https://doi.org/10.1093/oxfordjournals.aje.a118408
40. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015; 7 (309):309ra162. https://doi.org/10.1126/scitranslmed.aac4241 PMID: 26468324.
41. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nature communications. 2015; 6:7712. https://doi.org/10.1038/ ncomms8712 PMID: 26218507; PubMed Central PMCID: PMC4525294.
42. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988; 334 (6179):255–8. https://doi.org/10.1038/334255a0 PMID: 2456466
43. Golding B, Golding H, Preston S, Hernandez D, Beining PR, Manischewitz J, et al. Production of a novel antigen by conjugation of HIV-1 to Brucella abortus: studies of immunogenicity, isotype analysis, T-cell dependancy, and syncytia inhibition. AIDS Res Hum Retroviruses. 1991; 7(5):435–46. https://doi.org/10.1089/aid.1991.7.435 PMID: 1678617
44. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013; 19(12):1597–608. https://doi.org/10.1038/nm.3409 PMID: 24309663
45. Carter D, Reed SG. Role of adjuvants in modeling the immune response. Current opinion in HIV and AIDS. 2010; 5(5):409–13. https://doi.org/10.1097/COH.0b013e32833d2cdb PMID: 20978382; PubMed Central PMCID: PMC3894736.
46. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity. The Journal of Immunology. 2009; 183(10):6186. https://doi.org/10.4049/jimmunol.0901474 PMID: 19864596
47. Kim K-H, Lee Y-T, Hwang HS, Kwon Y-M, Jung Y-J, Lee Y, et al. Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells. PloS one. 2015; 10(10):e0139916. https://doi.org/10.1371/journal.pone.0139916 PMID: 26468884
48. Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. Vaccine. 2010; 28(34):5543–50. https://doi.org/10.1016/j.vaccine.2010.06.041 PMID: 20600502.
49. Cherukuri A, Stokes KL, Patton K, Kuo H, Sakamoto K, Lambert S, et al. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immunity & Ageing. 2012; 9(1):21. https://doi.org/10.1186/1742-4933-9-21 PMID: 23031690
50. Polack FP. Atypical Measles and Enhanced Respiratory Syncytial Virus Disease (ERD) Made Simple. Pediatr Res. 2007; 62(1):111–5. https://doi.org/10.1203/PDR.0b013e3180686ce0 PMID: 17515829
51. Collins PL, Fearns R, Graham BS. Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease. Current topics in microbiology and immunology. 2013; 372:3–38. doi: 10.1007/978-3-642-38919-1_1. PMC4794264. PMID: 24362682
52. Schneider-Ohrum K, Cayatte C, Bennett AS, Rajani GM, McTamney P, Nacel K, et al. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant. Journal of virology. 2017; 91(8). https://doi.org/10.1128/JVI. 02180-16 PMID: 28148790; PubMed Central PMCID: PMCPMC5375676.